Home > Healthcare > Medical Services > Diagnostic Services > Monkeypox Testing Market

Monkeypox Testing Market Trends

Report ID: GMI9634
Published Date: May 2024
Report Format: PDF

Download Free Sample

Monkeypox Testing Market Trends

The increasing prevalence of monkeypox cases is a significant driver for market. As cases rise, there is an urgent need to quickly identify and isolate infected individuals to prevent further spread. This drives the demand for reliable and rapid testing.

According to the U.S. Department of Health & Human Services, in 2023, at total of 95,912 monkeypox cases were reported globally.
Further, as per the same report, Brazil reported a surge in cases with 10,967 in 2023 along with 16 deaths. Thus, increased testing is crucial for monitoring and understanding the epidemiology of monkeypox, helping public health authorities track outbreaks and implement effective control measures.
Healthcare systems need to be equipped to handle outbreaks that includes having sufficient testing capabilities. Increased prevalence necessitates enhanced testing infrastructure and capacity. With more cases healthcare providers must have access to accurate diagnostic tools to distinguish monkeypox from other diseases with similar symptoms, such as chickenpox and smallpox.
Increased prevalence often leads to government funding and support for testing initiatives including grants for research and development of better diagnostic tools, thereby increasing the growth of the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global monkeypox testing industry size was valued at USD 1.7 billion in 2023 and is estimated to grow at 4.5% CAGR from 2024 to 2032 due to rapid diagnostic advancements, and growing government support.

The laboratory testing segment of the market accounted for USD 1.1 billion in 2023 due to its ability to provide precise detection of the monkeypox virus for ensuring high sensitivity and specificity.

The polymerase chain reaction (PCR) segment of the monkeypox testing market is forecasted to reach USD 1.3 billion by 2032 due to its high accuracy, rapid results, established technology, and crucial role in epidemiological studies and outbreak management.

Abbott Laboratories, Aegis Sciences Corporation, Applied DNA Sciences, Inc., Becton, Dickinson and Company, BioGX, bioMérieux SA, Bio-Rad Laboratories, Inc., CerTest Biotec, Creative Biogene, and Danaher Corporation, among others.